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Abstract: Two recent surveys of people who took psychedelic drugs and reported “God experience
encounters”, along with successful clinical trials using psychedelic therapy for depression, have
given rise to public misconceptions about psychedelics and atheism. Specifically, three inferences
have been drawn: (1) that the psychedelic experience tends to dissolve atheist convictions; (2) that
atheist convictions, once dissolved, are replaced with traditional monotheist beliefs; and (3) that
atheism and depression somehow correlate as afflictions for which psychedelic drugs offer relief. This
paper argues, based on analysis of the studies and trials along with relevant supplemental evidence,
that each of these popular inferences is substantially misleading. Survey data do not indicate that
most psychedelic atheists have cleanly cut ties with their former convictions, and there is strong
evidence that they have not traded atheism for traditional monotheism. Both personal testimony
and the effectiveness of microdose clinical trials serve to complicate any notion that a psychedelic
drug alleviates symptoms of depression by “curing” atheism. The paper then extends its focus to
argue that the broader field of neurotheology includes elements that contribute to these popular
misconceptions.
Keywords: psychedelic drugs; atheism; monotheism; pantheism; depression; neurotheology
Researchers at Johns Hopkins produced two recent studies related to psychedelic
drugs and their effects on philosophical perspective and religious identification (Griffiths
et al. 2019; Davis et al. 2020). Although the authors have academic appointments in Psy-
chiatry, Psychology, and Cognitive Neurosciences, their work has strong affiliations with
Religious Studies. The 2019 study was funded by the Council for Spiritual Practices, an
organization that has included prominent Religious Studies scholars among its advisors,
including Huston Smith and Ralph W. Hood. The study cites Smith’s influential essay
in which he argued, against R. C. Zaehner, for the validity of drug-occasioned mystical
experiences (Smith 1964; Zaehner 1961). Both the 2019 and the 2020 studies acknowledge
their indebtedness to Hood’s scale for measuring mystical experiences. Hood himself has
engaged in similar studies of psychedelic drugs and mystical experiences, collaborating
with Andrew Newberg—a principal expositor of the branch of Religious Studies commonly
known as Neurotheology (Yaden et al. 2016). Newberg, who has held positions in both
Psychology and Religious Studies at the University of Pennsylvania, considers Neurothe-
ology inherently multidisciplinary, with Religious Studies and Cognitive Neurosciences
bonding at its core (Newberg 2010). An earlier study of psilocybin and mystical experiences
led by Roland R. Griffiths, lead author of the 2019 study, has had significant influence on
neurotheological work (Griffiths et al. 2006). The two Johns Hopkins studies clearly belong
within this hybrid area of inquiry.
Given the limitations of working with Schedule I drugs, they based their work on sur-
veys of people who self-reported “God experience encounters” (in the first study) or “entity
encounters” (in the second study) occasioned by the use of a psychedelic. The first study,
which also compared a non-drug group with the much larger psychedelic group, gathered
information from participants who had taken either psilocybin, LSD, ayahuasca, or DMT
(Griffiths et al. 2019). The second study surveyed a group of people who reported having
experienced such encounters under the influence of DMT (Davis et al. 2020). For both
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studies, researchers harvested a significant number of participants: 3476 in the psychedelic
group for the first, and 2561 DMT users for the second.
These studies, along with clinical trials at Johns Hopkins and elsewhere that use
psychedelics to treat depression, have given rise to public misconceptions about psychedelic
drugs and atheism. Specifically, three inferences have been drawn: (1) that the psychedelic
experience tends to dissolve atheist convictions; (2) that atheist convictions, once dissolved,
are replaced by traditional monotheist beliefs; and (3) that atheism and depression some-
how correlate as afflictions for which psychedelic drugs offer relief. Each of these inferences,
though based to some degree on evidence from psychedelic studies, is significantly mis-
leading. These misconceptions have reinforced oversimplifications about atheism and its
alternatives and thereby impoverished popular debate about the subject.
It is particularly important to correct public misconceptions about such matters at this
cultural moment: the field of psychedelic therapy is growing rapidly despite substantial
legal obstacles. The field is growing not only with clinical trials in universities, but with
research conducted by an increasing number of entrepreneurs. Psychedelic research
necessarily brings with it political entanglements. In Canada, a team of six appointed
experts, including Religious Studies scholar Anne Vallely, recently submitted a report to
the government detailing recommendations for the safe implementation of psychedelic
use (Rochester et al. 2021). In the United States, political prospects for psychedelic drugs
seem more doubtful, at least in the short term. Already, ethical questions have been raised
about whether medical professionals ought to prescribe pharmaceuticals that alter patients’
political and religious beliefs (Jacobs 2020). Misinterpretation of the recent surveys of
psychedelic users could warp debate and undermine regulatory renovation.
Two headlines capture the spirit of popular response to the Johns Hopkins studies.
After the first study: “Is God Real? 62% of Atheist LSD Users Think So After a Mystical
Trip” (Potnis 2019). After the second study: “It’s Official: DMT Makes You Believe in
God” (Farah 2020). The headlines and the stories that accompany them convey both the
first and second misconceptions surrounding these studies—namely, that a psychedelic
trip is likely to persuade someone to abandon atheism and adopt traditional monotheism.
Apparent justification for the headlines came from one data point in each study. In the
first, “identification as atheist decreased significantly from before to after the experience”:
21% of the psychedelic group identified as atheist before the experience, but only 8% after
(Griffiths et al. 2019). The numbers were similar in the DMT study, with 28% identifying
as atheist before, and 10% after (Davis et al. 2020).
The first and most obvious weakness in popular inferences about psychedelics and
theistic belief has to do with the selective criterion for participation in the studies. The
first study surveyed only individuals who self-reported something that felt like a God
experience encounter. The DMT study asked for those who had experienced an entity
encounter, which might seem a more neutral term—but the authors elicited descriptions
of the entity with categories very similar to those used in the first study. Given that the
people surveyed constituted a special subset of psychedelic users—those who experienced
something that felt like an encounter with a godlike entity—it is notable and somewhat
surprising that as many as 534 of them continued to identify as atheist afterwards.
One of the co-authors of the 2019 study made this very point about the specially
selected survey group, in order to fend off a bioethicist’s complaint. The bioethicist had
cited the 2019 data about atheists and worried that the medical profession, ideally “neutral
and agnostic” on religious matters, might violate that neutrality if psychedelic therapy
should become a mainstream option (Jacobs 2020). Co-author Matthew Johnson countered
that “belief change of a religious type”, such as the reduction in the percentage of atheists
reported in his study, “would be massively inflated in this sample” (Johnson 2020).
However, there are other weaknesses besides the obvious problem of a selective survey
population. Even with analysis of just this special subset of psychedelic users, popular
inferences do not stand up to scrutiny. Survey data clearly do not support the second of
the inferences, the supposed conversion of atheists to traditional monotheism. Among
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the total psychedelic participants in the multi-drug study, “Identification as monotheist
significantly decreased and identification as Other significantly increased from before
to after the experience” (Griffiths et al. 2019). “Other” for the survey signified neither
monotheist nor atheist. In this survey, in fact, the vast majority—85%—chose “Other” as
their religious affiliation after a psychedelic drug occasioned a God experience encounter.
If the psychedelic experience was tempting people away from the atheist label, it certainly
did not move them into the camp of traditional monotheism.
It is reasonable to assume, then, that all or nearly all of those who identified as atheist
before their psychedelic encounters either continued to identify as atheist or chose to
identify neither as atheist nor monotheist. Contrary to the popular misconception, their
psychedelic experience did not convert them from atheism to belief in a traditional God.
There remains the question of what the shift from atheist to Other signifies. Does it mean
that the psychedelic experience, at least within this selective group, dissolved atheist
convictions?
Careful analysis of the two surveys suggests a more complex result. In the first
study, a key question asked participants to choose the “best descriptor of that which
was encountered”: “God (the God of your understanding)”, “Ultimate Reality”, “Higher
Power”, or “An Aspect or emissary of God (e. g., an angel)” (Griffiths et al. 2019). Data
for the psychedelic group—the full group, not just those who had identified as atheist—
indicated that a majority, 55%, chose “Ultimate Reality” as the best descriptor. Despite the
fact that the survey was framed with the term “God experience encounter”, the descriptor
“God” finished in third place, the choice of only 18%. Given that only 18% of the entire
psychedelic group chose God, it is likely that the atheist subset, only one-fifth of the group,
chose God in very small numbers, if at all.
In the DMT survey, where the before and after numbers for atheism were similar, the
study was framed with the more neutral term “entity encounter experience”. This study
also offered a question about God and Ultimate Reality, but in a form that made it unhelpful
for comparison with the first study. The DMT group was asked whether they “identified as
believing in Ultimate Reality, Higher Power, God, or Universal Divinity” (Davis et al. 2020).
The authors made note of a significant increase in these numbers: 36% answered yes before
the experience, 58% afterwards. Because the four entity descriptors were merged into
a single category, there can be no differentiating analysis of their separate implications.
Interestingly, however, the authors—all of whom worked on the 2019 study—borrowed
the first three descriptors from the earlier survey, but changed the order of listing. This
time, they arranged them in order of popularity from those earlier results, with Ultimate
Reality listed first, and God now third.
The descriptor Ultimate Reality took clear priority over God in the first study, and
although ambiguous survey construction clouded results in the second, Ultimate Reality
led the cluster of available descriptors. The number of atheists dropped from 21% to 8% in
the first study and from 28% to 10% in the second. If we posit that nearly all of those who
swerved away from atheism chose to identify as Other, and most of them encountered an
entity best described as Ultimate Reality, is a religious position so defined fundamentally
incompatible with atheism? This is the crucial question for evaluating the first popular
inference, about psychedelic experience dissolving atheist conviction.
The only data-driven help comes from the first survey. This study surveyed a non-drug
group, whose encounters came without the use of psychedelics. Members of this group
were much more likely than the psychedelic group to choose God as the best descriptor of
the entity (41% compared to 18%). For the non-drug group, God was the descriptor most
often chosen, in contrast with the psychedelic group, which favored Ultimate Reality. A few
statistically significant differences between the non-drug group and the psychedelic group
suggest how their choices of descriptor align with traditional notions of monotheism. These
all come from questions eliciting qualities of the entity encountered. Asked if the entity had
agency in this reality, the non-drug group agreed significantly more than the psychedelic
group. In a related question, as to whether the entity was petitionable, again the non-drug
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group agreed significantly more. The non-drug group also significantly differed from the
psychedelic group in the percentage characterizing the entity as benevolent (although a
majority of both groups thought it benevolent), and while only 1% of the non-drug group
checked “malicious”, 9% of the psychedelic group did. Taken together, the psychedelic
group, which favored Ultimate Reality as a descriptor, gave descriptive indicators much
less in agreement with traditional ideas of monotheism.
The survey is more helpful in providing hints about what Ultimate Reality is not than
about what it is. The phrase has the unfortunate distinction of being the vaguest of the
four descriptors. Survey participants who moved away from atheist to Other indicated
that a psychedelic experience had altered their views about the meaning of life, but did
not make them believe in God. The phrase Ultimate Reality perhaps offered a signifying
compromise. If “Ultimate” suggested some behind-the-curtain cosmic scheme they had
briefly glimpsed during their trip, “Reality” kept them in contact with the material world
of their former atheist convictions. Even though they chose to identify as Other rather than
atheist, their affiliation with Ultimate Reality did not amount to an irrevocable divorce
from their former worldview.
It would be helpful at this point to supplement data from the surveys with a more
informal online resource inspired by reports of the studies. A journalist found a handful of
subjects willing to talk: “Speaking to People Who Found God after Taking Psychedelics”
(Dawson 2020). All of these people profess some new version of faith, but their accounts
reveal complications. One subject evidently had read Strassman’s DMT: The Spirit Molecule,
because his trip report and new beliefs come straight from that book, with details of pineal
gland and third eye (Strassman 2000). His new credo may be set aside as the derivative
result of a suggestible mind. Another psychedelic convert, an artist who took LSD, came
by insights on his own, but his new theistic beliefs sound more like a version of pantheism
than traditional monotheism: “Now I feel like god is my mother, God is earth, God is
the universe, God is multidimensional”. The artist continues with reflections that were
common among LSD users in the psychedelic golden age of the 1960s, a kind of animist
enthusiasm: “LSD made it easier to notice magic in the most mundane parts of life. You
start to see nature breathing and dancing in this unique way” (Dawson 2020). Pantheism
carries “theism” in its root, but especially in its Spinozist form—Spinoza named “God
or Nature” as the foundation of being (Spinoza 2005, p. 98)—it is easy enough to make
pantheism compatible with atheism.
Another person included in this story found a new version of God because, like the
artist, she was finally “really seeing the world”. Her experience with DMT, she says, “made
me appreciate life more” (Dawson 2020). This person is of particular relevance because
she suffered from depression before her DMT epiphany, and credited the psychedelic
experience with relieving those symptoms. Her story does not line up perfectly as a test
case for the third popular inference—that atheism and depression somehow correlate as af-
flictions for which psychedelic drugs offer relief. This woman was not an atheist before her
psychedelic experience; she was Roman Catholic. Her psychedelic “conversion”, in other
words, moved her from a traditional monotheist belief to an alternative theism, something
that sounds more like the artist’s pantheism than another version of monotheism.
The robust test case for the correlation between atheism and depression comes from
Rachael Petersen. Petersen, a science writer and Visiting Fellow at the Harvard Divinity
School, participated in a Johns Hopkins clinical trial testing psilocybin as treatment for
severe depression. She wrote about her experience in a complex essay with a simple
title: “Taking Mushrooms for Depression Cured Me of My Atheism” (Petersen 2019). The
headline promises a story to validate the popular inference that psychedelics offer relief for
the correlated afflictions of atheism and depression.
Petersen explains that she became an atheist at age 12. As an adult, finding herself
unable to find relief for her symptoms by conventional therapies, she volunteered for the
psilocybin trial not knowing much: she had “chosen not to influence [her] trips by reading
literature on how psilocybin works”. Her experience caused her to move away from identi-
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fication as atheist, and her title seems to imply that the psychedelic drug simultaneously
led her to God and healed her depression. Petersen’s essay, however, suggests affiliations
more in line with the atheist “converts” of Griffiths’ 2019 study: religious identification
as Other, and description of the entity encountered as Ultimate Reality. Like the former
atheists of the survey, her new beliefs are not necessarily incompatible with atheism.
Petersen, in fact, uses the phrase “Ultimate Reality” twice as she describes the entity
she encountered during her trip. She says she felt “most comfortable” with that term.
(It seems likely that the Johns Hopkins interviewers in follow-up sessions worked with
prompts from a list similar to the one in the 2019 survey.) She names “God” only in a
hedging way: she encountered “what a religiously inclined person might label ‘God.’”
Even after her depressive symptoms returned, it was not God, but something Other, an
Ultimate Reality that she relied on for comfort— “the sense of being held by a great,
ineffable Beyond”. Following her psychedelic sessions, Petersen says, “I dedicated myself
to reading Buddhist texts, seeking some tradition to scaffold my changed world”. Tellingly,
she chose the one non-theistic tradition among major contemporary world religions.
Near the end of her essay, Petersen quotes the poet Wallace Stevens: “’God and
imagination are one.’ I don’t care if my encounters were ‘authentic’ or merely products of
an imagination turbo-charged by chemical compounds. They felt real . . . and are doing
interesting and real things in my life”. Here, her perspective aligns well enough with even
a devout atheist such as Richard Dawkins. Dawkins has not tried a psychedelic drug, but
he once said during a public forum that he “would actually like to do it” (Richard Dawkins
on Psychedelics 2012). He added that, should he do so, he would likely “interpret it as
a manifestation of what a wonderful thing the brain is, and how the brain can see and
experience even more things, under the right kinds of chemical stimulation”. Dawkins
would not summon the term “God” to make the point, but he would join with Wallace
Stevens and Petersen on an essential insight about the human imagination. If she no longer
identifies with the label “atheist”, because its implications do not match up well with her
psychedelic experience, she has not simply traded atheism for theism.
For people who have found relief from depression after taking large doses of psychedelic
drugs (often supplemented with psychotherapeutic sessions), the essence of the therapy
has to do with a radical change in perspective. As Petersen put it, “Why couldn’t they just
treat my illness without screwing with my worldview? But exploding one’s worldview is
the whole point of these treatments” (Petersen 2019).
It is the whole point of some of these treatments, but by no means all of them. An
increasing number of psychedelic clinical trials for depression and other mental disorders
use microdoses—doses too small to produce the classic mind-bending effects. These are
psychedelic treatments without the psychedelic experience, and therefore without the
“exploding worldview” effect that Petersen considered essential to her therapy. Both
models of psychedelic therapy have shown considerable promise in clinical trials, but
only the first model, deploying full dosage, invites suggestions about psychedelic drugs as
antagonists to atheism. In the second model, a very low dose of a psychedelic drug works
therapeutically at the micro-level of neurons, neurotransmitters, and synapses. Research
is still in the early stages, but scientists working with ketamine have theorized that the
drug alleviates depression by stimulating the growth of spines on dendrites, which helps
to generate synapses and increase brain plasticity (Makin 2019; Black 2021)
To conclude: each of these three inferences about psychedelic drugs and atheism that
has emerged in popular media is substantially misleading. Even the special subset of
psychedelic users who swerved away from identification as atheist after a God experience
encounter most often did so without definitive theistic convictions. Their new affiliations
with Other and Ultimate Reality, imprecise as they were, did not seem fundamentally
incompatible with atheism. For those who have found relief from depression through the
use of psychedelic drugs, in some cases, the drug also catalyzed a new religious perspective.
However, if evidence from the surveys of God experience encounters is reliably transferable,
very few of these new perspectives amount to conversions from atheism to traditional
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forms of monotheistic belief. Furthermore, psychedelic therapy for depression appears
to be just as effective at the microdose level, where religious worldviews—including
atheism—remain unaltered.
There remain two related questions to pursue. Did the study of God experience
encounters present its results in any way that might have encouraged the distorted public
interpretations of its atheist participants? More broadly, does the field of neurotheology
contain hints of an inhospitable attitude toward atheism?
One detail from the authors’ discussion of the 2019 results stands out. After they report
the percentage of participants who no longer identified as atheist after the experience, they
characterized these events as “sudden conversion experiences”: “This outcome is consistent
with sudden religious conversion experiences that are well described in the psychology
of religion, with Paul’s experience of encountering Jesus on the road to Damascus as the
prototype” (Griffiths et al. 2019, p. 22). By naming Paul’s experience as the prototype, they
reinforce the mistaken impression that the study’s atheists have converted to monotheism.
The comparison between Paul and the “convert” atheists of the 2019 study seems strained,
almost incongruous within the otherwise careful scientific prose. Paul’s conversion, not a
close match with survey results, subtly steers the discussion toward a Christian perspective.
A more neutral account comes in the abstract, which summarizes that the encounters
generally brought “moderate to strong persisting changes in life satisfaction, purpose and
meaning” (Griffiths et al. 2019, p. 1). Coming as it does immediately after the sentence
reporting the percentage of atheists who no longer identified as such, the abstract tempts
readers to infer some version of the third popular misconception: i. e., that atheists become
“happier” when they shed atheism.
Within the broader field of neurotheology, while no one has made a definitive claim
on experimental grounds, there have been relevant suggestions worthy of note. Hamer the-
orized that a religiously-inflected optimism correlates with a genetic predisposition involv-
ing certain brain functions, including the release of certain neurotransmitters (Hamer 2004).
Drawing on Hamer as well as the work of other researchers who found connections be-
tween religious activities and brain functions, notably frontal lobe activity and the release
of dopamine (Gianatti et al. 2001; Inzlicht et al. 2009; Schultz 2015), Newberg offered the
following speculative, “simplistic” model: “Perhaps if you have high dopamine levels
but low frontal lobe activity, you are more likely to be spiritual but not religious. And
perhaps if you have low activity in both, you are more likely to be an atheist” (Newberg
2018, p. 236).
This thread of content—that some form of religious belief, affiliation, or activity is
likely to correlate with a happier life—has a strong presence within neurotheological
research. Kept within strict scientific boundaries, of course, it stands or falls on its merits.
Newberg’s speculation about atheism and low dopamine and frontal lobe activity seems
incautious, however, as if betraying a tacit bias against atheism. Elsewhere, Newberg
asserts that “an ardent atheist ... would most likely not be considered a neurotheologian”
(Newberg 2010, p. 45).
The inhospitable attitude toward atheists is even more prominent in the flagship essay
from the recent special issue on neurotheology in Religions. W. R. Klemm reviews the
development of the field over the last few decades and offers thoughts about its future.
He recognizes that neurotheology has suffered growing pains because of its hybrid na-
ture: “Many scholars in both partnering areas are hostile to their partnering discipline”
(Klemm 2019, p. 4). For Klemm, the key to unifying neurotheology lies in what he calls a
“triune worldview”, which integrates “neuroscience, mental health, and religion”: “Neuro-
science can and should help us all lead more fulfilling and happy lives that are compatible
with sound spiritual values”. In his view, then, happiness is linked with something that
has theistic (even Christian) associations. The field’s proper goal is a therapeutic one, with
atheists a target for cure: “Neuroscience and mental health might help the agnostic and
atheist to recognize the narrowness and shallowness of their understanding”.
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To be clear: neurotheology makes no claim to offer proof or disproof regarding the
existence of God. As the authors of the 2019 study wrote, “It should be noted that neither
descriptive studies of such experiences, no matter how detailed, nor the emerging science
of neurotheology, no matter how strong the associations demonstrated between brain
processes and religious experience, can definitively address ontological claims about the
existence of God” (Griffiths et al. 2019, p. 22). However, neurotheologians must guard
against implicit theistic bias, and be wary of oversimplified models of atheism and atheists
that linger as templates within their structural schemes of analysis—especially when they
study something as complex as the psychedelic experience.
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